NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Fiche publication
Date publication
février 2017
Journal
European journal of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The NIACE (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status) score distinguishes different prognosis groups among BCLC A, B, and C HCC patients. Our aims are to evaluate the NIACE score and its additive value in two HCC cohorts treated either by surgery or by chemoembolization, and then according to the BCLC recommendations.
Mots clés
Aged, Carcinoma, Hepatocellular, blood, Chemoembolization, Therapeutic, adverse effects, Decision Support Techniques, Female, France, Health Status, Hepatectomy, adverse effects, Humans, Kaplan-Meier Estimate, Liver Neoplasms, blood, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, methods, Predictive Value of Tests, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, alpha-Fetoproteins, analysis
Référence
Eur J Gastroenterol Hepatol. 2017 Feb;: